Abstract
Background: Association between angiotensin‐converting enzyme (ACE) as well as apolipoprotein (apo) AI, B, and E polymorphisms and dyslipidemia and coronary artery disease (CAD) is controversial.
Hypothesis: This study assessed the distribution of ACE insertion/deletion, apo AI A/G mutation, apo B signal peptide insertion/deletion, apo B XbaI restriction fragment length, and apo E polymorphisms in 388 nondiabetic patients.
Methods: The study population included 112 patients with stable CAD, 139 patients with acute myocardial infarction (AMI), and 137 age‐matched control subjects.
Results: Univariate analysis showed higher prevalence of XbaI X+/X+ genotype in patients with CAD (p = 0.02). Angiotensin‐converting enzyme and apo polymorphisms were not associated with lipid levels or severity of CAD. When all genotypes known to be related to CAD, such as ACE DD, apo AI GG, apo B del/del, and XbaI X+X+, and E4 allele of apo E, were pooled, again no significant differences among groups were seen. Multivariate regression analysis disclosed traditional risk factors and elevated levels of apo B for men and reduced levels of apo AI for women as independent variables for CAD.
Conclusions: In addition to traditional coronary risk factors, apo B and AI could be considered predictors of CAD. No association between either form of CAD and polymorphisms was noted.
Keywords: coronary artery disease, angiotensin‐converting enzyme, apolipoprotein AI, apolipoprotein B, apolipoprotein E, gene polymorphism, genetics
Full Text
The Full Text of this article is available as a PDF (683.7 KB).
Reference
- 1. Nora JJ, Lortscher RH, Spangler RD, Nora AH, Kimberling WJ: Genetic‐epidemiologic study of early onset ischaemic heart disease. Circulation 1980; 61: 503–508 [DOI] [PubMed] [Google Scholar]
- 2. Hoit BD, Gilpin EA, Henning H, Maisel AA, Dittrich H, Carlisle J, Ross J Jr: Myocardial infarction in young patients: An analysis by age subsets. Circulation 1986; 74: 712–721 [DOI] [PubMed] [Google Scholar]
- 3. Marenberg ME, Risch N, Berkman LF, Floderus B, de Faire U: Genetic susceptibility to death from coronary heart disease in a study of twins. N Engl J Med 1994; 330: 1041–1046 [DOI] [PubMed] [Google Scholar]
- 4. Marian AJ: Genetic markers: Genes involved in human hypertension. J Cardiovasc Risk 1997; 4: 341–345 [PubMed] [Google Scholar]
- 5. Lusis AJ: Genetic factors affecting blood lipoproteins: The candidate gene approach. J Lipid Res 1988; 29: 397–429 [PubMed] [Google Scholar]
- 6. Samani NJ, O'Toole L, Channer K, Woods KL: A meta‐analysis of the association of the deletion allele of the angiotensin‐converting enzyme gene with myocardial infarction. Circulation 1996; 94: 708–712 [DOI] [PubMed] [Google Scholar]
- 7. Wilson PWF, Schaefer EJ, Larson MG, Ordovas JM: Apolipo‐protein E alleles and risk of coronary disease. A meta‐analysis. Arterioscler Thromb Vasc Biol 1996; 16: 1250–1255 [DOI] [PubMed] [Google Scholar]
- 8. Freidewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low‐density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499–502 [PubMed] [Google Scholar]
- 9. Saiki RK, Gelfand DH, Stoffel S, Scharf SJ, Higuchi R, Horn GT, Mullis KB, Erlich HA: Primer‐directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science 1988; 239: 487–491 [DOI] [PubMed] [Google Scholar]
- 10. Lindpaintner K, Pfeffer MA, Kreutz R, Stampfer MJ, Grodstein F, LaMotte F, Buring J, Hennekens CH: A prospective evaluation of an angiotensin‐converting‐enzyme gene polymorphism and the risk of ischemic heart disease. N Engl J Med 1995; 332: 706–711 [DOI] [PubMed] [Google Scholar]
- 11. Pagani F, Sidoli A, Giudici, GA, Vergani C, Baralle EE: Association of a polymorphism in the apo AI gene promoter with hyperalphalipoproteinemia In: Biotechnology of Dyslipoproteinemias: Applications in Diagnosis and Control (Eds. Lenfant C, Paoletti R, Catapano AL, Albertini A.). New York, NY: Raven Press, 1990. [Google Scholar]
- 12. Pajukanta PE, Valsta LM, Aro A, Pietinen P, Heliö T, Tikkanen MJ: The effects of the apolipoprotein B signal peptide (ins/del) and Xbal polymorphisms on plasma lipid responses to dietary change. Atherosclerosis 1993; 122: 1–10 [DOI] [PubMed] [Google Scholar]
- 13. Zevelin A, Rosenberg N, Peretz H, Amit Y, Kornbrot N, Seligsohn U: Improved method for genotyping apolipoprotein E polymorphisms by a PCR‐based assay simultaneously utilizing two distinct restriction enzymes. Clin Chem 1997; 43: 1657–1659 [PubMed] [Google Scholar]
- 14. Cambien F, Poirier O, Lecerf L, Evans A, Cambou J‐P, Arveiler D, Luc G, Bard J‐M, Bara L, Ricard S, Tiret L, Amouyel P, Alhenc‐Gelas F, Soubrier F: Deletion polymorphism in the gene for angiotensin‐converting enzyme is a potent risk factor for myocardial infarction. Nature 1992; 359: 641–643 [DOI] [PubMed] [Google Scholar]
- 15. Lindpaintner K, Pfeffer MA, Kreutz R, Stampfer MJ, Grodstein F, LaMotte F, Buring J, Hennekens CH: A prospective evaluation of an angiotensin‐converting‐enzyme gene polymorphism and the risk of ischemic heart disease. N Engl J Med 1995; 332: 706–711 [DOI] [PubMed] [Google Scholar]
- 16. Régis‐Bailly A, Fournier B, Steinmetz J, Gueguen R, Siest G, Visvikis S: Apo B signal peptide insertion/deletion polymorphism is involved in postprandial lipoparticles' responses. Atherosclerosis 1995; 118: 23–34 [DOI] [PubMed] [Google Scholar]
- 17. Lopez‐Miranda J, Ordovas JM, Espino A, Marin C, Salas J, Lopez‐Segura F, Jimenez‐Pereperez J, Perez‐Gimenez F: Influence of mutation in human apolipoprotein A‐I promoter on plasma LDL cholesterol response to dietary fat. Lancet 1994; 343: 1246–1249 [DOI] [PubMed] [Google Scholar]
- 18. McCarthy BJ: Polymorphisms and markers associated with apolipoprotein B. Curr Opin Lipidol 1991; 2: 81–85 [Google Scholar]
- 19. Hegele RA, Huang LS, Herbert PN, Blum CB, Buring JE, Hennekens CH, Breslow JL: Apolipoprotein B‐gene DNA polymorphisms associated with myocardial infarction. N Engl J Med 1986; 315: 1509–1515 [DOI] [PubMed] [Google Scholar]
- 20. Peacock R, Dunning A, Hamsten A, Tornvall P, Humphies S, Talmud P: Apolipoprotein B gene polymorphisms, lipoproteins and coronary atherosclerosis: A study of young myocardial infarction survivors and healthy population‐based individuals. Atherosclerosis 1992; 92: 151–164 [DOI] [PubMed] [Google Scholar]
- 21. Calabresi L, Franceschini G: High density lipoprotein and coronary heart disease: Insights from mutations leading to low high density lipoprotein. Curr Opin Lipidol 1997; 8: 219–224 [DOI] [PubMed] [Google Scholar]
- 22. Lehtinen S, Lehtimäki T, Sisto T, Salenius J‐P, Nikkilä M, Jokela H, Koivula T, Ebeling F, Ehnholm C: Apolipoprotein E polymorphism, serum lipids, myocardial infarction and severity of angiographically verified coronary artery disease in men and women. Atherosclerosis 1995; 114: 83–91 [DOI] [PubMed] [Google Scholar]
- 23. Damaraju S, Yu QT, Safavi F, Marian AJ: Apolipoprotein E4 is not a risk factor for coronary artery disease or restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol 1995; 75: 1181–1183 [DOI] [PubMed] [Google Scholar]
- 24. Reilly SL, Ferrel RE, Sing CF: The gender‐specific apolipoprotein E genotype influence on the distribution of plasma lipids and apolipoproteins in the population of Rochester, Minn. III: Correlations and covariances. Am J Hum Genet 1994; 55: 1001–1018 [PMC free article] [PubMed] [Google Scholar]
- 25. Marshall HW, Morrison LC, Wu LL, Anderson JL, Corneli PS, Stauffer DM, Allen A, Karagounis LA, Ward RH: Apolipoprotein polymorphisms fail to define risk of coronary artery disease. Results of a prospective, angiographically controlled study. Circulation 1994; 89: 567–577 [DOI] [PubMed] [Google Scholar]
- 26. Humphies SE: DNA polymorphisms of the apolipoprotein genes—their use in the investigation of the genetic component of hyperlipidaemia and atherosclerosis. Atherosclerosis 1988; 72: 89–108 [DOI] [PubMed] [Google Scholar]
- 27. Smith JD, Brinton EA, Breslow JL: Polymorphism in the human apolipoprotein A‐I gene promoter region. Association of the minor allele with decreased production rate in vivo and promoter in vitro. J Clin Invest 1992; 89: 1796–1800 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28. Angotti E, Mele E, Costanzo F, Avvedimento EV: A polymorphism (GA transition) in the –78 position of the apolipoprotein A‐I promoter increases transcription efficiency. J Biol Chem 1994; 269: 17371–17374 [PubMed] [Google Scholar]
- 29. Danek GM, Valenti M, Baralle FE, Romano M: The A/G polymorphism in the –78 position of the apolipoprotein A‐I promoter does not have a direct effect on transcriptional efficiency. Biochim Biophys Acta 1998; 1398: 67–74 [DOI] [PubMed] [Google Scholar]
- 30. Wang XL, Liu SX, del McCredie, Wilcken : Polymorphisms at the 5′‐end of the apolipoprotein AI gene and severity of coronary artery disease. J Clin Invest 1996; 98: 372–377 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31. Davignon J, Gregg RE, Sing CF: Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis 1988; 8: 1–21 [DOI] [PubMed] [Google Scholar]
- 32. Luc G, Bard J, Arveiler D, Evans A, Cambou J, Bingham A, Amouyel P, Schaffer P, Ruidavets J, Cambien F, Fruchart J, Ducimetiere P: Impact of apolipoprotein E polymorphism on lipoproteins and risk of myocardial infarction: The ECTIM Study. Arterioscler Thromb 1994; 14: 1412–1419 [DOI] [PubMed] [Google Scholar]
- 33. Wilson PWF, Myers RH, Larson MG, Ordovas JM, Wolf PA, Schaefer EJ: Apolipoprotein E alleles, dyslipidemia, and coronary heart disease: The Framingham Offspring Study. J Am Med Assoc 1994; 272: 1666–1671 [PubMed] [Google Scholar]
- 34. Laan M, Paabo S: Demographic history and linkage disequilibrium in human populations. Nat Genet 1997; 17: 435–438 [DOI] [PubMed] [Google Scholar]
- 35. McKeigue PM: Mapping genes underlying ethnic differences in disease risk by linkage disequilibrium in recently admixed populations. Am J Hum Genet 1997; 60: 188–196 [PMC free article] [PubMed] [Google Scholar]